<DOC>
	<DOCNO>NCT00537836</DOCNO>
	<brief_summary>The primary goal plan study investigate efficacy safety ZK 283197 dosage 2 3 mg ingested daily period 8 week treatment hot flush . In order able ass efficacy test substance , compare efficacy 1 mg Estradiol placebo . The comparator Estradiol certify hormone preparation , already use treatment hot flush standard treatment . After pass screening , volunteer start run-in phase follow 8 week treatment follow-up phase . 112 postmenopausal woman hot flush without relevant prior disease participate three European country ( 2 study site Germany , 1 study site Great Britain 1 study site The Netherlands ) study .</brief_summary>
	<brief_title>ZK283197 Treatment Vasomotor Symptoms</brief_title>
	<detailed_description />
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Women least 35 moderate severe hot flush seven consecutive day Body mass index ( BMI ) : 20 30 kg/m² ( inclusive ) Postmenopausal status Contraindication use hormonal therapy Prior hysterectomy Hormonal therapy intrauterine hormone release device within 4 week prior study entry longacting injectable implant 6 month prior study entry Repeated intake medication affect study aim</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Hot flush</keyword>
	<keyword>Therapy hot flush</keyword>
	<keyword>17ß-estradiol ( E2 )</keyword>
	<keyword>Hormone replacement therapy</keyword>
</DOC>